title: Effect of Paclitaxel-eluting versus sirolimus-eluting stents on coronary restenosis in Korean diabetic patients.
abstract: BACKGROUND
  With the introduction of drug-eluting stents (DES), the angiographic rates of restenosis have reduced dramatically but less prominently in diabetic patients. We compared the effects of sirolimus-eluting stents (SES) versus paclitaxel-eluting stents (PES) on 6-month angiographic and clinical outcomes in Korean diabetic patients.
  
  
  METHODS
  Diabetic patients with de novo coronary lesions (169 patients with 190 lesions) were randomly assigned to either SES or PES in six different cardiovascular centers from April 2005 to January 2006. Patients with vessel size >2.0 mm and < or =2 vessel diseases requiring < or =2 DES implantation were included in the study.
  
  
  RESULTS
  Baseline clinical and angiographic characteristics were similar between the two groups. At 6-month follow-up, the late lumen loss (0.26 +/- 0.76 in the SES group vs. 0.39 +/- 0.92 mm in the PES group, P = 0.356) and the rate of binary restenosis (2.8%[n = 2] in the SES group vs. 6.9%[n = 5] in the PES group, P = 0.441) showed no significant differences. Rates of death (1.2%[n = 1] in the SES group vs. 1.2%[n = 1] in the PES group, P = 1.000), myocardial infarction (1.2%[n = 1] in the SES group vs. 1.2%[n = 1] in the PES group, P = 1.000), and target lesion revascularization (2.4%[n = 2] in the SES group vs. 4.8%[n = 4] in the PES group, P = 0.443) were similar in both groups during 6 months of follow-up.
  
  
  CONCLUSIONS
  The use of either SES or PES demonstrated similar 6-month angiographic and clinical outcomes in Korean diabetic patients with coronary artery disease.
authors.affiliation: Department of Cardiology, Dong-A University Hospital, Busan, Korea.
authors.forename: Moo Hyun
authors.initials: MH
authors.lastname: Kim
authors.forename: Soon Jun
authors.initials: SJ
authors.lastname: Hong
authors.forename: Kwang Soo
authors.initials: KS
authors.lastname: Cha
authors.forename: Hun Sik
authors.initials: HS
authors.lastname: Park
authors.forename: Shung Chull
authors.initials: SC
authors.lastname: Chae
authors.forename: Seung Ho
authors.initials: SH
authors.lastname: Hur
authors.forename: Hyeon Cheol
authors.initials: HC
authors.lastname: Gwon
authors.forename: Jang Ho
authors.initials: JH
authors.lastname: Bae
authors.forename: Do-Sun
authors.initials: DS
authors.lastname: Lim
mesh_terms: D000368:Aged; D019917:Blood Vessel Prosthesis Implantation / Q000295:instrumentation*; D017023:Coronary Angiography; D023921:Coronary Stenosis / Q000000981:diagnostic imaging / Q000517:prevention & control* / Q000601:surgery; D003925:Diabetic Angiopathies / Q000000981:diagnostic imaging / Q000517:prevention & control* / Q000601:surgery; D054855:Drug-Eluting Stents; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007723:Korea; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use*; D011446:Prospective Studies; D055502:Secondary Prevention; D020123:Sirolimus / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D017239:Paclitaxel; D020123:Sirolimus